







MolProbity Ramachandran analysis

pembrolizumab_abb2_1FH.pdb, model 1



97.4% (221/227) of all residues were in favored (98%) regions.
99.6% (226/227) of all residues were in allowed (>99.8%) regions.

There were 1 outliers (phi, psi):
L. 57 Ala (61.1, -14.0)